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Abstract
Purpose:  To  determine  adrenal  gland  volume  (AGV)  in  women  with  polycystic  ovary  syndrome
(PCOS) by  comparison  with  healthy  control  subjects  and  to  investigate  the  relationship  between
AGV and  hormonal  status.
Patients  and  methods:  AGV  was  measured  on  transverse  sections  of  T1-weighted  MRI  imaging
data in  27  PCOS  patients  and  40  age-matched  control  subjects  for  this  prospectively  designed
study. A  comparative  analysis  of  AGV  in  PCOS  and  controls  was  performed  and  possible  corre-
lations between  AGV  and  hormonal  parameters  were  evaluated.
Results:  PCOS  patients  had  signiﬁcantly  larger  AGV  compared  to  controls  ((11.7  ±  4.4  cm3,
7.2 ±  1.9  cm3,  respectively,  P  <  0.001).  A  signiﬁcant  positive  correlation  was  found  between
total AGV  and  dehydroepiandrosterone  sulfate,  17-OH  progesterone,  and  total  and  free  testos-
terone levels  in  the  PCOS  group  (r  =  +0.51,  +0.48,  +0.43,  +0.62,  respectively;  P  values  <  0.05).
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In  addition,  AGV  was  signiﬁcantly  negatively  correlated  with  LH  and  LH/FSH  ratio  in  the  PCOS
group (r  =  −0.55,  P  =  0.02;  r  =  −0.51,  P  =  0.01,  respectively).
Conclusions:  PCOS  patients  have  signiﬁcantly  increased  AGV  as  well  as  a  positive  correlation
of AGV  and  androgens.  We  conclude  that  the  assessment  of  AGV  with  MRI  shows  a  signiﬁcant
correlation  with  the  androgenic  activity  of  the  gland,  and  that  hypertrophy  of  the  adrenal  gland
may be  involved  in  the  pathogenesis  of  PCOS.
© 2015  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
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Molycystic  ovary  syndrome  (PCOS),  also  called  hyperandro-
enic  anovulation,  is  the  most  frequent  endocrine  disorder,
ffecting  approximately  5—10%  of  women  of  reproduc-
ive  age  [1].  It  is  not  a  simple  pathophysiologic  process,
eing  characterized  by  anovulation,  irregular  menstruation,
ypergonadotrophism,  hirsutism,  obesity  and  excess  andro-
enic  hormones  and  is  commonly  associated  with  infertility
1,2].
Androgen  excess  is  the  principal  characteristic  of  the  dis-
ase  and  it  has  been  suggested  that  PCOS  should  primarily
e  regarded  as  a  disorder  of  increased  androgen  synthesis,
se,  or  metabolism  [2].  While  the  ovary  is  generally  con-
idered  the  principal  source  of  androgens  in  most  of  these
atients,  over  50%  of  patients  with  PCOS  also  demonstrate
xcess  levels  of  adrenal  androgens  (AAs),  particularly  dehy-
roepiandrosterone  sulfate  (DHEA-S)  [3,4].  These  patients
how  hypersecretion  of  adrenocortical  products,  both  in
asal  conditions  and  in  response  to  stimulation  of  adreno-
orticotropic  hormone  (ACTH)  [5—9].
Some  signs  of  hyperactivity  of  the  adrenal  glands  should
e  present  if  the  AA  excess  plays  a  major  role  in  the  patho-
enesis  of  PCOS.  It  has  been  suggested  that  disorders  that
re  accompanied  by  chronic  activation  of  the  HPA  axis  are
enerally  associated  with  enlargement  of  the  adrenal  glands
10—13].  Thus,  AGV  may  represent  a  non-invasive  measure
f  HPA  axis  tone  and  is  suggested  to  be  an  indicator  of
drenal  gland  activity  [12—15].
Although  CT  is  the  preferred  primary  modality  for  adrenal
maging  due  to  its  outstanding  spatial  resolution,  MRI  is
lso  considered  to  be  a  potentially  reliable  technique  for
drenal  imaging,  without  using  radiation.  Additionally,  with
mprovements  in  magnetic  resonance  volumetric  analysis,
RI  has  become  a  useful  alternative  method  for  assess-
ng  a  pathological  change  in  adrenal  size,  particularly  in
xploratory  studies.  With  this  background,  we  have  mea-
ured  the  volumes  of  adrenal  glands  in  PCOS  patients  using
RI  and  have  investigated  the  correlation  of  adrenal  vol-
mes  with  adrenal  androgens.
The  purpose  of  the  present  study  was  to  evaluate  the
ffect  of  PCOS  on  adrenal  gland  volume  and  to  eluci-
ate  whether  possible  morphologic  abnormalities  of  adrenal
lands  could  explain  the  hyperandrogenism  in  PCOS.  Addi-
ionally,  we  aimed  to  explore  the  hypothesis  that  AGV  could
rovide  a  surrogate  measure  of  androgenic  activity  of  the
land.  To  the  best  of  our  knowledge,  this  is  the  ﬁrst  study
nvestigating  the  possible  morphological  changes  of  adrenal
A
o
tlands  and  the  relationship  between  AGV  and  androgens  in
omen  with  PCOS.
atients and methods
atients
his  prospectively  designed  cross-sectional  study  was  car-
ied  out  between  June  2014  to  August  2014  in  the  radiology
epartment  of  our  university  hospital.  The  study  was  per-
ormed  in  accordance  with  the  Declaration  of  Helsinki  and
as  approved  by  the  local  Ethical  Committee.  Informed
onsent  was  obtained  from  all  included  subjects  before  par-
icipation  in  the  study.  All  women  with  PCOS  were  recruited
rom  those  who  visited  our  obstetrics  and  gynecology  outpa-
ient  facility  with  a  chief  complaint  of  irregular  menstrual
ycles  and/or  clinical  hyperandrogenism.  All  participants
nderwent  a gynecologic  examination,  including  transvagi-
al/pelvic  ultrasound  to  investigate  ovarian  morphology.
he  diagnosis  of  PCOS  was  based  on  the  Rotterdam  criteria
16].
The  patient  group  consisted  of  27  normal-weight  women
ith  PCOS  (mean  age  22.1  ±  3.8  years)  and  40  aged  and  BMI-
atched  female  volunteers  with  normal  ovulating  cycles
28  ±  2  days,  blood  progesterone  levels  >  10  ng/ml  in  two
onsecutive  cycles),  no  signs  of  hyperandrogenism,  and  nor-
al  ultrasonographic  appearance  of  the  ovaries.
Body  mass  index  (BMI,  kg/m2) was  calculated  by  divid-
ng  weight  in  kilograms  (kg)  by  height  in  meters  squared
m2)  to  assess  obesity.  All  the  study  population  had  a  nor-
al  abdomen  MRI  as  evaluated  by  a  radiologist.  Also,  none
f  the  women  studied  had  any  systemic  disease  that  could
ossibly  affect  their  reproductive  physiology.  Exclusion  cri-
eria  for  all  women  were  age  <  16  or  >  35  years,  body  mass
ndex  (BMI)  <  17.5  kg/m2 or  >  25  kg/m2 and  possible  causes
f  adrenal  enlargement  such  as:  congenital  adrenal  hyper-
lasia,  Cushing’s  syndrome,  primary  aldosteronism,  multiple
ndocrine  neoplasia  type  1,  chronic  infection,  neoplastic
rocesses,  type  2 diabetes  and  depression.
RI data acquisitionll  subjects  underwent  non-contrast  MRI  of  the  abdomen
n  a 1.5-Tesla  Philips  Intera  MR  unit  (Philips  Medical  Sys-
ems,  Amsterdam,  The  Netherlands)  on  the  3rd—7th day  of
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their  spontaneous  menstrual  cycle.  The  adrenal  glands  were
imaged  using  T1-weighted  fast  spin  echo  technique  with  the
following  parameters:  repetition  time  (TR)  =  450  ms,  echo
time  (TE)  =  5.2  ms,  matrix  =  574  ×  574,  ﬂip  angle  =  10◦,  ﬁeld
of  view  =  300  mm,  slice  thickness  =  2  mm.  The  MRIs  were
blindly  assessed  by  an  experienced  radiologist  (E.K),  i.e.,
the  radiologist  did  not  know  whether  the  abdominal  MRI
scans  belonged  to  a  patient  with  PCOS  or  to  a  subject  from
the  healthy  control  group.
Image analysis
The  MRI  data  were  transferred  to  a  DELL  Precision  Worksta-
tion  for  anatomical  volume  measurements  of  the  right  and
left  adrenal  glands.  Each  adrenal  gland  was  manually  traced
on  axial  slice  of  T1  sequence  MRI.  A  segmentation  process
was  performed  in  order  to  use  images  for  3D  reconstruction.
Segmentation  was  performed  on  a  slice-by-slice  basis  using
manual  tools  to  deﬁne  the  contour  around  the  gland.  Collec-
tion  of  data  and  the  segmentation  process  were  performed
using  Mimics  10.1  software  (Materialise,  Leuven,  Belgium).
The  segmentation  process  was  converted  to  a  3D  mesh  model
using  an  adapted  marching  cubes  algorithm  and  the  volume
value  was  obtained  (Fig.  1)  [17].  Measurements  were  per-
formed  by  two  radiologists  with  segmentation  experience
(EU,  MBA).  The  overall  Pearson  correlation  for  interobserver
reliability,  assessed  on  10  randomly  selected  images,  was
0.95  and  intrarater  reliability,  based  on  10  scans  measured
twice  by  the  same  rater  (EU)  was  0.97.  All  these  values  are
well  within  acceptable  limits.
Serum hormone level measurements
Fasting  blood  samples  were  collected  for  measurements  of
serum  levels  of  FSH,  LH,  estradiol,  DHEA-S,  17-OH  proges-
terone,  total  testosterone  (Ttest),  free  testosterone  (Ftest)
and  prolactin  between  the  3rd and  7th days  of  the  men-
strual  cycle  in  controls  and  after  a  spontaneous  bleeding
episode  in  patients  with  PCOS.  Also,  a  1-mg  dexametha-
sone  suppression  test  was  performed  to  exclude  Cushing’s
syndrome.
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Figure 1. Each adrenal gland was manually traced on axial slice of T1
order to use images for 3D reconstruction and was converted to a 3D me59
tatistical analysis
tatistical  analysis  was  performed  using  SPSS,  version  19.0
SPSS,  Chicago,  IL).  Mann-Whitney  U test  was  used  for  com-
arison  of  groups  for  variables  that  were  inconsistent  with  a
ormal  distribution.  Independent  student  t-test  was  used  for
omparison  of  groups  for  variables  that  were  consistent  with
 normal  distribution.  P  <  0.05  was  considered  statistically
igniﬁcant.
A multiple  linear  regression  model  was  used  for  deter-
ination  of  the  relation  between  adrenal  volume  and
ndependent  variables.  Pearson’s  correlation  coefﬁcient
nd  Spearman’s  correlation  coefﬁcient  test  were  used  for
omparisons  of  adrenal  volume  alterations  with  age  and  hor-
onal  parameters.  Intra-observer  reliability  was  evaluated
ith  use  of  the  Pearson  correlation  coefﬁcient.
esults
aseline  characteristics  of  patients  with  PCOS  and  controls
re  presented  in  Table  1. Patients  with  PCOS  had  a  total
GV  of  11.7  cm3, whereas  healthy  control  subjects  had  a
olume  of  7.2  cm3. Statistical  analysis  showed  total  adrenal
olume  to  be  signiﬁcantly  higher  in  patients  with  PCOS  than
n  healthy  control  subjects  (P  <  0.001)  (Fig.  2).  Correlation
nalysis  showed  that  in  PCOS  subjects,  total  AGV  was  signiﬁ-
antly  higher  in  older  individuals  (r  =  0.42,  P =  0.05),  whereas
ealthy  control  subjects  showed  a  trend  toward  decreasing
GV  with  age  but  without  reaching  statistical  signiﬁcance
r  =  −0.05,  P  =  0.7,  Pearson  correlation  coefﬁcient)  (Table  2)
Fig.  3).  Serum  LH,  LH/FSH  ratio,  DHEA-S,  17-OH  proges-
erone  and  Ftest  levels  were  signiﬁcantly  higher  in  the  PCOS
roup  (P  <  0.05).
AGV  correlated  strongly  with  DHEA-S  levels  (r  =  0.51,
 =  0.008),  and  also  with  Ftest,  Ttest  (r  =  0.43,  P  =  0.03  and
 =  0.62,  P =  0.002,  respectively)  and  17-OH  progesterone
lasma  levels  (r  = 0.48,  P  =  0.01).  However,  there  was  a  sig-
iﬁcant  negative  correlation  between  LH,  LH/FSH  ratio  and
GV  (r  =  −0.55,  P  =  0.02,  r  =  −0.51,  P  =  0.01,  respectively)
Table  2).  There  was  no  signiﬁcant  correlation  between  AGV
-weighted MR sequence. A segmentation process was performed in
sh model using an adapted marching cubes algorithm.
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Table  1  Baseline  characteristics  of  patients  with  PCOS  and  controls.
PCOS  (n  =  27)  Control  (n  =  40)  P-value
Age  (years)  22.1  ±  3.8  23.1  ±  1.5  0.1a
BMI  (kg/m2)  24.5  ±  2.1  22.1  ±  1.7  0.8a
Adrenal  volume  (cm3)  11.7  ±  4.4  7.2  ±  1.9  0.00*a
LH  (mIU/ml)  10  ±  10.8  5  ±  6.8  0.00*b
FSH  (mIU/ml)  6.1  ±  2.1  5.2  0.7a
LH/FSH  1.59  ±  1.82  0.9  ±  0.8  0.03*b
DHEAS  (g/dL) 311  ±  133  242  ±  100  0.01*a
Free  testosterone  (ng/dl)
Total  testosterone  (ng/dl)
2.7 ±  2.3
37.9  ±  23.6
1.0 ±  0.4
35  ±  28.6
0.00*a0.2b
Estradiol  (pg/ml) 39.3  ±  33  42.5  ±  35  0.9b
17-OH  progesterone  (ng/ml) 0.95  ±  0.4 0.39  ±  0.7  0.03*a
BMI: body mass index; LH: luteinizing hormone; FSH: follicle-stimulating hormone; DHEA-S: dehydroepiandrosterone sulfate.
*Signiﬁcant differences were signed (if P < 0.05).
a Independent sample t-test (was used for normally distributed variables that was showed as mean ± standart deviation).
b Mann Whitney U-test (was used for not-normally distributed variables that was showed as median (interquartile range) (IQR).
Figure 2. Adrenal gland volumes across groups. Adrenal volumes
are signiﬁcantly higher in patients with PCOS than in healthy control
subjects (P < 0.00).
Figure 3. Correlations of adrenal gland volumes with age. Total
adrenal gland volume was signiﬁcantly higher in older individuals
in patients with PCOS (r = 0.42, P = 0.05) whereas healthy control
subjects showed a trend toward decreasing gland volume with age
(r: −0.05, P = 0.7).
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n  the  other  hand,  LH  was  also  negatively  correlated  with
HEA-S  in  women  with  PCOS  (r  =  −0.46,  P  =  0.01,  Spearman
orrelation  Coefﬁcient)  whereas  there  was  no  signiﬁcant
orrelation  between  LH  and  DHEA-S  in  healthy  control  sub-
ects  (r  =  0.09  P  =  0.6).  Also,  multiple  linear  regression  model
esults  showed  that  there  were  no  independent  variables
ffecting  AGV.
iscussion
he  main  ﬁndings  of  the  present  study  were  as  follows:  an
ncrease  in  AGV  in  normal  weight  PCOS  patients  compared
ith  age  and  BMI  matched  healthy  controls  was  noted.  Fur-
hermore,  AGV’s  were  positively  correlated  with  DHEA-S,
Table  2  Correlation  coefﬁcients  between  total  adrenal
volume  and  age,  hormonal  parameters  in  women  with
PCOS.
Rho  P
Age  (years)  0.42  0.05a
LH  (mIU/ml)  −0.55  0.02b
LH/FSH  −0.51  0.01b
DHEA-S  (g/dL)  0.51  0.008a
Free  testosterone
(ng/dl)
Total  testosterone
(ng/dl)
0.43
0.62
0.03a0.002b
Estradiol  (pg/ml)  −0.18  0.3b
17  OH  progesterone
(ng/ml)
0.48 0.01a
LH: luteinizing hormone; DHEA-S: dehydroepiandrosterone
sulfate.
a Pearson’s correlation coefﬁcient.
b Spearman’s correlation coefﬁcient.
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17-OH  progesterone,  Ttest,  and  Ftest  and  were  negatively
correlated  with  LH  levels  in  PCOS  patients,  but  there  was  no
signiﬁcant  correlation  between  these  parameters  in  healthy
subjects.  Finally,  a  signiﬁcant  positive  correlation  between
AGV  and  age  was  noted  in  PCOS  patients,  whereas  non-
signiﬁcant  trends  toward  a  decrease  in  AGV  were  found  in
the  healthy  group.  The  ﬁndings  were  consistent  with  our
previous  hypothesis  that  increased  androgen  levels  in  PCOS
are  associated  with  hypertrophy  of  the  adrenal  gland,  which
can  be  an  issue  in  PCOS  pathogenesis.
As  is  well  known,  approximately  half  of  PCOS  women
have  functional  adrenocortical  hyperandrogenism  [3].  These
women  vary  in  their  presentation  [18],  but  are  most  com-
monly  identiﬁed  by  increased  basal  levels  of  DHEA-S  both
in  the  basal  condition  [4,19]  and  in  response  to  ACTH
stimulation  [5,9,20,21].  The  mechanisms  underlying  the
exaggerated  response  to  ACTH  in  PCOS  are  still  uncer-
tain.  While  some  studies  showed  high  ACTH  levels  [6,8]  and
hyperresponsiveness  of  ACTH  to  corticotropin-releasing  hor-
mone  (CRH)  [22],  others  showed  normal  ACTH  plasma  levels
[2,22—26]  or  hyperresponsiveness  of  the  adrenal  to  ACTH
[5,8,9,22]  in  PCOS  patients.  Brieﬂy,  the  larger  question  is
whether  the  hyperandrogenic  state  is  due  to  abnormalities
of  hypothalamic-pituitary  control  or  due  to  an  alteration  in
the  intrinsic  behaviour  of  the  adrenal  cortex.
Although  many  studies  have  examined  AA  excess  in
patients  with  PCOS  [3—5,7—9,22—24],  the  role  of  the
adrenal  gland  in  the  genesis  of  PCOS  and  the  mecha-
nisms  responsible  for  the  adrenal  hyperandrogenism  in  these
women  are  still  unresolved  problems.  To  date,  the  main
focus  of  interest  concerning  patients  with  PCOS  has  been
on  metabolic  and  hormonal  alterations  and  thus,  these  have
been  extensively  studied.  Since  AA  overproduction  plays  a
major  role  in  the  pathogenesis  of  PCOS,  some  signs  of  hyper-
activity  of  the  adrenal  glands  should  exist.  Our  analysis
showed  that  volume  of  the  adrenal  gland,  which  we  inves-
tigated  by  means  of  1.5  T  MRI,  was  signiﬁcantly  larger  in
patients  with  PCOS  than  in  control  subjects.  To  the  best  of
our  knowledge,  this  is  the  ﬁrst  study  showing  objective  mea-
surable  morphological  changes  in  the  adrenal  gland  and  its
relationship  to  androgens  in  women  with  PCOS.
In  the  present  study,  volumes  of  the  adrenal  glands  were
measured  by  means  of  MRI.  Basically,  CT  is  the  preferred
imaging  modality  for  adrenal  glands  because  of  its  better
spatial  resolution,  low  cost  and  broad  availability.  However,
despite  these  beneﬁts  of  CT,  the  major  disadvantage  is  the
inevitable  patient  exposure  to  ionizing  radiation.  Thus,  MRI
is  a  useful  alternative  modality  in  clinical  practice,  espe-
cially  with  the  need  of  repeated  assessment  of  the  adrenal
gland,  for  instance,  for  follow-up  of  tumor  size.  Additionally,
MRI  is  considered  to  be  a  potentially  reliable  technique  for
adrenal  imaging  because  of  its  high-contrast,  high-resolution
and  multiplanar  imaging  capability.  To  date,  there  have  been
only  a  few  volumetric  studies  using  MRI  for  measuring  AGV
[13—15,25,26].  This  may  be  partly  due  to  the  paucity  of
information  about  the  reliability  of  MRI  volumetric  analysis.
However,  a  recent  research  report  sought  to  determine  the
intra-  and  inter-observer  variation  and  repeatability  of  MRI
measurements  of  AGV  and  suggested  that  MRI  has  become
a  potentially  alternative  imaging  modality  for  the  measure-
ment  of  AGV  in  humans,  due  to  the  increasing  capabilities
of  MRI  volumetric  analysis  [26].
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The  mean  volumes  of  adrenal  glands  in  healthy  adults
eported  in  previous  studies  were  variable,  with  a  median
eft  adrenal  volume  of  2.53  ±  0.80  ml  [12], 5.7  ±  4.9  ml  [27]
nd  4.23  ±  0.74  [28]. Also,  a  recent  study  performed  by
rant  et  al.  reported  that  adrenal  volume  varied  from
.63  cm3 to  3.68  cm3 [26].  Another  volumetric  study  of
n  Asian  population  measured  AGV  using  CT,  and  noted
hat  the  left,  right,  and  total  AGV  were  4.23  ±  0.74
range:  2.85—5.83)  cm3, 4.26  ±  0.86  (2.59—6.56)  cm3, and
.50  ±  1.40  (5.80—11.39)  cm3,  respectively  [28]. In  our
tudy,  healthy  control  subjects  had  a  mean  total  AGV  of  7.2
m3, whereas  patients  with  PCOS  had  signiﬁcantly  enlarged
drenal  glands  with  a  total  AGV  of  11.7  cm3.
Under  normal  conditions,  HPA  axis  activation,  in  response
o  physiological  or  psychological  stress,  results  in  release  of
RH  from  the  hypothalamus,  which  stimulates  the  produc-
ion  of  ACTH  from  the  anterior  pituitary.  Subsequently,  ACTH
timulates  the  zona  fasciculata  of  the  adrenal  cortex  to  pro-
uce  more  glucucorticoids.  However,  chronic  activation  of
he  HPA  axis  results  in  an  increase  of  AGV  because  of  the
rophic  effects  of  ACTH  on  the  adrenal  cortex.  Thus,  AGV
s  accepted  as  a  non-invasive  measure  of  HPA  axis  tone  (11,
3).
Adrenocortical  hyperplasia  may  result  from  endocrine
bnormalities  such  as  Cushing’s  syndrome,  primary  aldos-
eronism,  CAH  or  multiple  endocrine  neoplasia  type  1
29]. It  has  also  been  demonstrated  that  11.3%  of  patients
ndergoing  CT  without  endocrine  disease  have  adrenal
nlargement  as  an  incidental  radiological  ﬁnding  [30].  This
roup  includes  benign  adrenocortical  hyperplasia,  which  is
eﬁned  as  radiographic  adrenal  enlargement  of  unknown
ause,  also  inﬂammation,  neoplastic  processes  [31—34],
ype  2  diabetes  [11],  or  psychiatric  disorders,  such  as
epression  [12]  and  blumia  [13]. It  has  been  suggested  that
here  could  be  upregulation  of  the  HPA  axis  and  this  could
eﬂect  overworking  of  the  adrenal  glands,  making  them
nlarged  or  swollen.  In  addition,  in  all  these  disorders,  the
ncreased  AGV  is  thought  to  be  due  to  chronic  ACTH  eleva-
ion.  However,  in  previous  studies,  no  signiﬁcant  differences
ere  found  in  terms  of  ACTH  levels  between  PCOS  patients
nd  the  healthy  population  [4,22—24].  Azziz  et  al.  suggested
hat  high  levels  of  adrenal  androgens  in  PCOS  patients  were
he  result  of  increased  zona  reticularis  mass,  which  we  also
ound  in  the  present  study.  These  authors  also  concluded
hat  AA  excess  in  PCOS  was  not  due  to  increased  ACTH  levels
r  increased  sensitivity  of  these  androgens  to  ACTH  stimu-
ation  [4]. In  our  recent  study  on  PCOS,  we  found  that  PCOS
omen  had  higher  pituitary  volumes  than  healthy  women,
s  well  as  a  positive  correlation  between  pituitary  gland
olume  and  LH  levels  [35].  We  also  demonstrated  that  PGV
egan  to  rise  before  ovarian  volume  increased,  suggesting
his  as  an  early  ﬁnding  of  PCOS.  Thus,  we  concluded  that
hronic  stimulation  with  LH  may  lead  to  an  increase  in  ovar-
an  volume  in  later  stages  of  the  disease.  Similarly,  in  the
resent  study,  it  seems  likely  that  subtle  but  chronic  stimu-
ation  with  ACTH,  as  a  result  of  overactivity  of  the  HPA  axis,
ay  result  in  subclinical  hypertrophy  and/or  hyperplasia  of
he  zonae  reticularis/fasciculata.
DHEA-S  is  the  most  abundant  androgen  produced  by  the
drenal  cortex  and,  therefore,  is  used  as  a  marker  of  AA
ecretion.  Also,  17-OH  progesterone  is  primarily  produced
n  the  adrenal  glands  and  to  some  degree  in  the  gonads
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1].  Our  analysis  showed  that  serum  DHEA-S,  17-OH  proges-
erone  and  Ftest  levels  were  signiﬁcantly  higher  in  the  PCOS
omen,  and  that  patients  with  higher  DHEA-S  and  17-OH
rogesterone  levels  had  larger  adrenal  volumes.  Our  study
lso  demonstrated  that  Ftest  and  Ttest  levels  showed  pos-
tive  correlations  with  DHEA-S  levels  and  with  AGV  in  PCOS
omen,  but  no  correlations  were  found  in  controls.  This  was
n  expected  ﬁnding  since  DHEA  and  its  sulfate  ester,  DHEA-S,
ay  undergo  continuous  interconversion  and  also  convert  to
estosterone  and  androstenedione  in  peripheral  tissues  [36].
lthough  the  ovaries  are  known  to  be  the  major  source  of
estosterone,  50%  of  circulating  testosterone  is  derived  from
he  conversion  of  AAs  in  normal  women  of  reproductive  age
37].  Hence,  high  levels  of  AAs  may  always  be  accompanied
y  elevated  gonadal  androgen  levels,  as  also  shown  in  our
tudy.
In  addition,  we  found  a  signiﬁcant  negative  correlation
etween  DHEA-S  and  LH  levels.  These  ﬁndings  are  incon-
istent  with  some  human  and  animal  studies  [38—40]  that
ound  a  positive  correlation  between  LH  and  DHEA-S  levels
nd  support  the  idea  that  high  LH  levels  might  be  responsible
or  the  adrenocortical  hyperactivity.  In  contrast,  the  present
tudy  showed  that  higher  DHEA-S  levels  were  associated
ith  lower  LH  levels  in  patients  with  PCOS.  We  suggest  that
igh  testosterone  levels,  which  are  the  result  of  increased
eripheral  conversion  of  high  DHEAS  levels,  give  rise  to  a
ecrease  in  LH  levels  because  of  a  negative-feedback  effect.
Our  analysis  showed  that  PCOS  patients  showed  a  signif-
cant  increase  in  adrenal  volume  with  age.  However,  in  our
ontrol  group,  AGV  did  not  change  signiﬁcantly  with  age  but
howed  a  trend  toward  decreasing  with  age,  which  is  in  line
ith  the  ﬁndings  of  Wang  et  al.  [28].  Puurunen  et  al.  found
hat  serum  adrenal  steroid  production  capacity  remained
nhanced  at  least  up  to  menopause  in  women  with  PCOS  [9].
herefore,  it  is  reasonable  for  us  to  speculate  that  enlarge-
ent  of  the  adrenal  gland  with  age  in  PCOS  may  reﬂect  more
hronically  elevated  levels  of  DHEA-S  and  an  ongoing  process
f  gland  hypertrophy  in  the  course  of  time  and  duration  of
he  disease  from  puberty  to  menopause.
Additionally,  but  beyond  the  scope  of  this  paper,  is  the
act  that  there  is  growing  evidence  of  a  link  between  PCOS
nd  depression,  anxiety,  bipolar  disorder  and  binge  eat-
ng  disorder.  On  the  other  hand,  patients  suffering  from
drenal  hyperplasia  are  often  mistakenly  thought  to  have
COS  because  of  the  excess  production  of  androgen  and
yperandrogenism  [34].  Although  all  other  causes  of  adrenal
nlargement  as  we  discussed  above  were  excluded  from  our
tudy,  it  could  be  hypothesized  that  all  these  diseases  that
re  associated  with  each  other  may  be  a  reﬂection  of  a
ommon  pathogenesis.
There  are  limitations  of  the  present  study  that  should
e  noted.  Firstly,  we  designed  our  study  with  basal  andro-
ens  and  routine  hormonal  parameters,  which  was  sufﬁcient
or  the  diagnosis  of  PCOS.  For  this  reason,  laboratory
ndings  concerning,  insulin  and  IGF-1  levels,  which  may  con-
ribute  to  adrenal  gland  enlargement,  and  also  ACTH  levels,
ere  not  available.  Although  our  study  was  performed  with
ormal-weight  women  to  exclude  the  possibility  of  hyperin-
ulinemia,  further  research  with  a  full  endocrine  assessment
s  warranted.  The  other  weakness  of  our  study  was  the  lim-
ted  number  of  subjects  fulﬁlling  the  inclusion  criteria  (BMI,
ormonal  status,  and  age).  On  the  other  hand,  statisticallyE.  Unlu  et  al.
igniﬁcant  correlations  were  found  even  though  the  sample
ize  was  small.
In conclusion,  we  have  found  a  signiﬁcant  increase  of  AGV
n  patients  with  PCOS  compared  to  healthy  control  individu-
ls,  previously  not  reported,  as  well  as  a  positive  correlation
f  adrenal  gland  size  and  androgens.  Adrenal  androgen
xcess  in  PCOS  appears  to  be  due  to  an  alteration  in  the
ntrinsic  behavior  of  the  adrenal  cortex  (subclinical  hyper-
rophy  and/or  hyperplasia  of  zonae  reticularis/fasciculata)
nd  hyperactivity  of  the  adrenal  glands.  Understanding  the
elationship  between  adrenal  volume  and  adrenal  steroido-
enesis  in  PCOS  might  provide  novel  insights  into  the
athophysiology  of  the  syndrome.
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